Ruben Van Dijck
Erasmus MC Cancer Institute(NL)
Publications by Year
Research Areas
Myeloproliferative Neoplasms: Diagnosis and Treatment, Multiple Myeloma Research and Treatments, Chronic Myeloid Leukemia Treatments, Lymphoma Diagnosis and Treatment, Hemoglobinopathies and Related Disorders
Most-Cited Works
- → Luspatercept as Potential Treatment for Congenital Sideroblastic Anemia(2023)13 cited
- → The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma(2021)12 cited
- → Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis(2025)9 cited
- → COVID‐19‐associated pseudothrombocytopenia(2021)9 cited
- → Blinatumomab in relapsed/refractory diffuse large B cell lymphoma(2017)3 cited
- → S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL(2023)3 cited
- → Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial(2026)
- → Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined(2025)
- → Fedratinib for patients with myelofibrosis(2025)
- → Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis(2025)